Osteoporosis inducidapor glucocorticoides
Análisis de las guías internacionales de prevención y tratamiento
Resumen
La osteoporosis inducida por glucocorticoides (OIG) es la segunda causa etiológica de osteoporosis luego de la posmenopáusica y la principal de las secundarias. La pérdida de masa ósea varía del 10 al 40% dependiendo del sitio examinado, la duración del tratamiento, la enfermedad de base y el glucocorticoide (GC) y la dosis utilizadas, y afecta predominantemente al hueso trabecular. El riesgo de fractura aumenta rápidamente dentro de los primeros 3 a 6 meses luego del comienzo de la terapia con GC y se mantiene en una fase lenta de pérdida ósea en tiempos prolongados de tratamiento con un mayor riesgo de fracturas vertebrales. Este riesgo revierte rápidamente al discontinuar los GC, pero permanece, sin embargo (en diferente escala), un mayor riesgo relativo de fracturas en relación con la población no expuesta.Citas
I. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993-1000.
II. Adinoff AD, Hollister JR. Steroid-induced fractu-res and bone loss in patients with asthma. N Engl J Med-1983; 309:265-8.
III. van Staa TP, Leufkens HG, Cooper C. The epide-miology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13:777-87.
IV. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: patho-physiology and therapy. Osteoporos Int 2007; 18:1319-28.
V. Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocor-ticoid-induced osteoporosis. Osteoporos Int 2005; 16:2168-74.
VI. Gonnelli S, Caffarelli C, Maggi S, et al. Effect of inhaled glucocorticoids and beta (2) agonists on vertebral fracture risk in COPD patients: the EOLO study. Calcif Tissue Int 2010; 87:137-43.
VII. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recom-mendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010; 62:1515-26.
VIII. Hansen KE, Wilson HA, Zapalowski C, Fink HA, Minisola S, Adler RA. Uncertainties in the pre-vention and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res 2011; 26:1989-96.
IX. Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteo-porosis. Osteoporos Int 2012; 23:2257-76.
X. Leib ES, Saag KG, Adachi JD, et al; FRAX(®) Position Development Conference Members. Official Positions for FRAX(®) clinical regarding gluco-corticoids: the impact of the use of glucocorticoids on the estimate by FRAX(®) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clini-cal Densitometry and International Osteoporosis Foundation on FRAX(®). J Clin Densitom 2011; 14(3):212-9.
XI. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011; 22(3):809-16.
XII. Schurman L, Bagur A, Claus-Hermberg H, et al. Guías 2012 para el diagnóstico, la prevención y el tratamiento de la osteoporosis. Medicina (B Aires) 2013; 73:55-74.
XIII. Pozzo MJ. Vitamina D. Acciones no clásicas. Ac-tual Osteol 2005; 1:28-33.
XIV. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 up-date. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteopo-rosis. Arthritis Rheum 2001; 44:1496-503.
XV. Working group in collaboration with The Royal Co-llege of Physicians, The Bone and Tooth Society of Great Britain, and The National Osteoporosis So-ciety. Glucocorticoid-induced osteoporosis. 2002.
XVI. Schurman L, Bagur A, Claus-Hermberg H, et al. Guías para diagnóstico, prevención y tratamiento de la osteoporosis 2007. Consenso SAO-AAOMM. Actual Osteol 2007; 3:120-35.
XVII. U S Food and Drug Administration. www.fda.gov. Acceso: marzo 2013.
XVIII. Administración Nacional de Medicamentos, Ali-mentos y Tecnología Médica (ANMAT). www. anmat.gov.ar. Acceso: marzo 2013.
XIX. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339:292-9.
XX. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, pla-cebo-controlled extension trial. Arthritis Rheum 2001; 44:202-11.
XXI. Wallach S, Cohen S, Reid DM, et al. Effects of ri-sedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Cal-cif Tissue Int 2000; 67:277-85.
XXII. Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001; 69:242-7.
XXIII. Reid DM, Devogelaer JP, Saag K, et al. Zoledro-nic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, dou-ble-dummy, randomised controlled trial. Lancet 2009; 373:1253-63.
XXIV. Roux C, Reid DM, Devogelaer JP, et al. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glu-cocorticoid-induced osteoporosis. Osteoporos Int 2012; 23:1083-90.
XXV. Sambrook PN, Roux C, Devogelaer JP, et al. Bis-phosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone 2012; 50:289-95.
XXVI. Hakala M, Kröguer H, Valleala H, et al. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postme-nopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, ran-domized, double-blind, placebo-controlled trial. Scand J Rheumatol 2012; 41:260-6.
XXVII. Losada I, Sartori L, Di Gianantonio E, Zen M, Clementi M, Doria A. Bisphosphonates in patients with autoimmune rheumatic diseases: can they be used in women of childbearing age? Autoimmun Rev 2010; 9:547-52.
XXVIII. L angdahl BL, Marin F, Shane E, et al. Te-riparatida versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009; 20:2095-104.
XXIX. S aag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, dou-ble-blind, controlled trial. Arthritis Rheum 2009; 60:3346-55.
XXX. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporo-sis. N Engl J Med 2007; 357:2028-39.
XXXI. Glüer CC, Marin F, Ringe JD, et al. Comparative effects of teriparatida and risedronate in gluco-corticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 2013. doi: 10.1002/jbmr.1870.
XXXII. Karras D, Stoykov I, Lems WF, et al. Effectiveness of teriparatida in postmenopausal women with os-teoporosis and glucocorticoid use: 3-year results from the EFOS study. J Rheumatol 2012; 39:600-9.
XXXIII. Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3):321-33.
XXXIV. Hofbauer LC, Zeitz U, Schoppet M, Skalicky M, Schüler C, Stolina M, et al. Prevention of glucocor-ticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum 2009; 60:1427-37.
XXXV. Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphos-phonates. Ann Rheum Dis 2010; 69:872-5.
Derechos de autor 2014 Revista Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
